Etzer Darout, an analyst from BMO Capital, has initiated a new Buy rating on Scholar Rock Holding (SRRK). Etzer Darout’s buy rating for Scholar Rock Holding stems from a variety of factors. Firstly, ...

A UConn professor and researcher who 28 years ago discovered a gene for a protein that limits human muscle growth is closer than ever to having that work play a significant role in treating those with ...

Scholar Rock Inc. has announced plans to advance SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity, toward an IND submission in 2025.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolism Scholar Rock’s novel myostatin inhibitor, SRK-439, is part of its ...

- Data support that Scholar Rock’s unique approach to selective myostatin inhibition could improve body composition in people living with obesity and on an existing background treatment - Scholar Rock ...

“A blessing and a curse” is how Harry Aikines-Aryeetey describes the genetic quirk that means his body carries more muscle mass than the average human.

Company plans to expand into cardiometabolic disorders, leveraging its experience in myostatin inhibition Preclinical data support advancing SRK-439, a novel investigational myostatin inhibitor for ...

KAWASAKI, Japan--(BUSINESS WIRE)-- PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced the ...